Drug intelligence / Profile preview

EHT899

Development stage: Preclinical
Lead developer: Enzo Biochem
Modality: Recombinant Proteins and Enzymes

Overview

EHT899 is a proprietary immunomodulatory therapy developed for the treatment of hepatitis B virus (HBV) infection. It is a formulation based on an HBV viral protein, designed to modulate the immune response and eliminate the undesirable immune activation associated with chronic HBV infection. The drug aims to alter host immunity in order to better control or clear HBV by reducing harmful immune responses that contribute to liver pathology[1][2][3][4].

Beyond the preview

Go deeper on EHT899.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EHT899.

Explore the full profile